---
title: 'Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits,
  innovation, trials, endpoints, quality of life, value, and price'
date: '2024-09-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39320645/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240925194808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Over the past two decades, the development of innovative
  and effective drugs transformed the treatment landscape for breast cancer patients.
  Yet, investigators and regulators must safeguard that highly-priced new drugs demonstrate
  improvements in patient-centered clinical endpoints: overall survival and quality
  of ...'
disable_comments: true
---
CONCLUSIONS: Over the past two decades, the development of innovative and effective drugs transformed the treatment landscape for breast cancer patients. Yet, investigators and regulators must safeguard that highly-priced new drugs demonstrate improvements in patient-centered clinical endpoints: overall survival and quality of ...